Free tool
FAERS Monitor: Provocholine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019193 or its brand name (Provocholine, Methacholine Chloride). Reports on generic versions are filed under their own applications.
Reports
73
Serious
36
49% of reports
Hospitalization
14
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chest discomfort8
- dyspnoea7
- fatigue7
- headache6
- dizziness5
- drug ineffective5
- urticaria5
- angioedema4
- anxiety4
- asthma4
- benign prostatic hyperplasia4
- pain4
- accidental exposure to product3
- arthralgia3
- back pain3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 3 |
| 2013 | 1 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 7 |
| 2020 | 8 |
| 2021 | 3 |
| 2022 | 7 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,086 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| benign prostatic hyperplasiaSignal | 4 | 223.6 | 86.2 | 677 |
| angioedemaSignal | 4 | 26.1 | 10.0 | 73 |
| chest discomfortSignal | 8 | 22.5 | 11.7 | 144 |
| asthmaSignal | 4 | 10.2 | 3.9 | 25 |
| urticariaSignal | 5 | 8.6 | 3.7 | 27 |
| accidental exposure to productSignal | 3 | 8.4 | 2.8 | 13 |
| anxietySignal | 4 | 4.0 | 1.6 | 6 |
| back pain | 3 | 3.7 | 1.2 | 4 |
| dyspnoeaSignal | 7 | 3.6 | 1.8 | 11 |
| dizzinessSignal | 5 | 2.9 | 1.2 | 5 |
| headacheSignal | 6 | 2.8 | 1.3 | 5 |
| fatigueSignal | 7 | 2.6 | 1.3 | 6 |
| arthralgia | 3 | 2.1 | 0.7 | 1 |
| pain | 4 | 1.9 | 0.7 | 1 |
| drug ineffective | 5 | 1.1 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.